[go: up one dir, main page]

FI891689A - Som antiinflammatoriska och antidegenerativa medel anvaendbara nya substituerade azetidinoner. - Google Patents

Som antiinflammatoriska och antidegenerativa medel anvaendbara nya substituerade azetidinoner. Download PDF

Info

Publication number
FI891689A
FI891689A FI891689A FI891689A FI891689A FI 891689 A FI891689 A FI 891689A FI 891689 A FI891689 A FI 891689A FI 891689 A FI891689 A FI 891689A FI 891689 A FI891689 A FI 891689A
Authority
FI
Finland
Prior art keywords
azetidinoner
antiinflammatoriska
antidegenerativa
substituerade
anvaendbara
Prior art date
Application number
FI891689A
Other languages
English (en)
Finnish (fi)
Other versions
FI891689A0 (fi
Inventor
Shrenik K Shah
Paul E Finke
James B Doherty
William Hagmann
Peter L Barker
Conrad P Dorn
Raymond A Firestone
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI891689A0 publication Critical patent/FI891689A0/fi
Publication of FI891689A publication Critical patent/FI891689A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Reinforced Plastic Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI891689A 1988-04-11 1989-04-10 Som antiinflammatoriska och antidegenerativa medel anvaendbara nya substituerade azetidinoner. FI891689A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17968888A 1988-04-11 1988-04-11

Publications (2)

Publication Number Publication Date
FI891689A0 FI891689A0 (fi) 1989-04-10
FI891689A true FI891689A (fi) 1989-10-12

Family

ID=22657566

Family Applications (1)

Application Number Title Priority Date Filing Date
FI891689A FI891689A (fi) 1988-04-11 1989-04-10 Som antiinflammatoriska och antidegenerativa medel anvaendbara nya substituerade azetidinoner.

Country Status (21)

Country Link
EP (1) EP0337549B1 (no)
JP (1) JP2736113B2 (no)
KR (1) KR930008223B1 (no)
CN (1) CN1037144A (no)
AT (1) ATE128704T1 (no)
AU (1) AU621865B2 (no)
CA (1) CA1337990C (no)
DE (1) DE68924439T2 (no)
DK (1) DK169329B1 (no)
ES (1) ES2079373T3 (no)
FI (1) FI891689A (no)
GR (1) GR3017656T3 (no)
HU (1) HUT50761A (no)
IE (1) IE891140L (no)
IL (1) IL89835A0 (no)
LV (1) LV11459B (no)
NO (1) NO891470L (no)
NZ (1) NZ228600A (no)
PT (1) PT90222B (no)
YU (1) YU71489A (no)
ZA (1) ZA892549B (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229381A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229510A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
KR930700494A (ko) * 1990-04-10 1993-03-15 시게루 미즈노 신규한 옥사디논 유도체
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
GB9103654D0 (en) * 1991-02-21 1991-04-10 Merck Sharp & Dohme Chemical process
US5104862A (en) * 1991-03-20 1992-04-14 Merck & Co., Inc. Bethalactam elastase inhibitors containing phosphorous acid derivatives at the 4-position of the 2-azetidinone
US5100880A (en) * 1991-03-20 1992-03-31 Merck & Co., Inc. Novel betalactam elastase inhibitors containing phosphorous acid derivatives at the 4-position of the 2-azetidinone
US5348953A (en) * 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1993000332A1 (en) 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
EP0596015B1 (en) * 1991-07-23 1997-10-01 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5229267A (en) * 1991-08-26 1993-07-20 Merck & Co., Inc. Assay for evaluating inhibition of PMN elastase by N-substituted azetidinones
US5274080A (en) * 1991-08-26 1993-12-28 Merck & Co., Inc. Monospecific antibodies useful in evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones
US5276139A (en) * 1991-08-26 1994-01-04 Merck & Co., Inc. Haptens useful in evaluating inhibition of PNN elastase by N-substituted azetidinones
EP0529719A1 (en) * 1991-08-26 1993-03-03 Merck & Co. Inc. Assay for evaluating inhibition of PMN elastase by N-Substituted Azetidinones
US5149838A (en) * 1991-09-20 1992-09-22 Merck & Co., Inc. Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents
GB2266527A (en) * 1992-03-17 1993-11-03 Merck & Co Inc Substituted azetidinones useful in the treatment of leukemia
US5250676A (en) * 1992-03-23 1993-10-05 University Of Notre Dame Du Lac Process for the preparation of 3-substituted-2-azetidinones
CA2108584C (en) * 1992-10-27 1998-11-24 James B. Doherty Substituted azetidinones as anti-inflammatory and antidegenerative agents
JPH08502752A (ja) * 1992-10-27 1996-03-26 メルク エンド カンパニー インコーポレーテッド 抗炎症剤及び抗変性剤としての新規の置換アゼチジノン
US5591737A (en) * 1992-12-17 1997-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1994013636A1 (en) * 1992-12-17 1994-06-23 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
GB9314350D0 (en) * 1993-07-12 1993-08-25 Zeneca Ltd Armide derivatives
US5420010A (en) * 1993-07-30 1995-05-30 Merck & Co., Inc. Assay for evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5403952A (en) * 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
AU686780B2 (en) * 1994-03-11 1998-02-12 Merck & Co., Inc. Composition for the treatment of lung disease
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
AU5014496A (en) * 1995-03-23 1996-10-08 Japan Tobacco Inc. Diphenylmethyl-azetidinone compounds and elastase inhibitor
US5747485A (en) * 1995-04-13 1998-05-05 Merck & Co., Inc. Substituted azetidiones as anti-inflammatory and antidegenerative agents
US5523233A (en) * 1995-05-03 1996-06-04 Merck & Co., Inc. Enzymatic hydrolysis of 3,3-diethyl-4-[(4-carboxy)phenoxy]-2-azetidinone esters
TR199701762T1 (xx) * 1995-07-01 1998-05-21 Smithkline Beecham P.L.C. Damar t�kanmas� tedavisi i�in azetidinon t�revleri.
AU7222196A (en) * 1995-10-09 1997-04-30 Chiroscience Limited Azetidinones and their therapeutic use as cytokine inhibitors
JP2000502079A (ja) * 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
CZ341098A3 (cs) * 1996-04-26 1999-03-17 Smithkline Beecham Plc Azetidinonové deriváty pro ošetřování aterosklerózy
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
WO1999018073A1 (en) * 1997-10-07 1999-04-15 Boehringer Ingelheim (Canada) Ltd. Azetidinone derivatives for the treatment of hcmv infections
JP2001519329A (ja) * 1997-10-07 2001-10-23 ベーリンガー インゲルハイム （カナダ） リミテッド Ｈｃｍｖ感染症の治療用のアゼチジノン誘導体
ES2187063T3 (es) * 1997-10-07 2003-05-16 Boehringer Ingelheim Ca Ltd Derivados de azetidinona para el tratamiento de infecciones por hcmv.
AU8059598A (en) * 1998-06-11 1999-12-30 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
AU4654199A (en) * 1998-07-23 2000-02-14 Shionogi & Co., Ltd. Monocyclic beta-lactam compounds and chymase inhibitors containing the same
AU4343500A (en) 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DK1413331T3 (da) 2001-01-26 2007-12-10 Schering Corp Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivatoren fenofibrat og sterolabsorptionsinhibitoren ezetimib til vaskulære indikationer
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
ATE331512T1 (de) 2001-01-26 2006-07-15 Schering Corp Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
RS50386B (sr) 2001-03-28 2009-12-31 Schering Corporation, Enantioselektivna sinteza intermedijarnih jedinjenja azetidinona
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20040092499A1 (en) 2002-11-06 2004-05-13 Schering Corporation Methods and therapeutic combinations for the treatment of autoimmune disorders
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1601669B1 (en) 2003-03-07 2008-12-24 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US8440819B2 (en) * 2008-02-22 2013-05-14 Allergan, Inc. Therapeutic substituted beta-lactams

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents

Also Published As

Publication number Publication date
EP0337549A1 (en) 1989-10-18
JP2736113B2 (ja) 1998-04-02
DE68924439D1 (de) 1995-11-09
ATE128704T1 (de) 1995-10-15
AU3263089A (en) 1989-10-12
LV11459B (en) 1996-12-20
KR900016121A (ko) 1990-11-12
HUT50761A (en) 1990-03-28
GR3017656T3 (en) 1996-01-31
DK169329B1 (da) 1994-10-10
ES2079373T3 (es) 1996-01-16
JPH026471A (ja) 1990-01-10
DE68924439T2 (de) 1996-05-09
FI891689A0 (fi) 1989-04-10
PT90222A (pt) 1989-11-10
IE891140L (en) 1989-10-11
NO891470D0 (no) 1989-04-10
NZ228600A (en) 1992-02-25
PT90222B (pt) 1994-07-29
KR930008223B1 (ko) 1993-08-27
DK170589A (da) 1989-10-12
EP0337549B1 (en) 1995-10-04
YU71489A (en) 1991-10-31
IL89835A0 (en) 1989-12-15
ZA892549B (en) 1989-11-29
LV11459A (lv) 1996-08-20
CA1337990C (en) 1996-01-23
NO891470L (no) 1989-10-12
AU621865B2 (en) 1992-03-26
DK170589D0 (da) 1989-04-10
CN1037144A (zh) 1989-11-15

Similar Documents

Publication Publication Date Title
FI891689A0 (fi) Som antiinflammatoriska och antidegenerativa medel anvaendbara nya substituerade azetidinoner.
ES553821A0 (es) Un procedimiento para la preparacion de nuevas azetidinonas sustituidas.
FI874839A0 (fi) Nya substituerade kefalosporinsulfoner anvaendbara som antiinflammatoriska och antidegenerativa medel.
FI924310A (fi) Nya 2-substituerade indan-2-karboxialkylderivat anvaendbara som inhibitorer av enkefalinas och ace
DK0393936T3 (da) 3-substituerede 2-oxindolderivater som antiinflammatoriske midler
FI931163A (fi) Kompositioner innehaollande kombinationer av ytaktiva medel och baernstensyraacyleringsmedelderivat eller hydroxiaromatiska aemnen och anvaendning av dessa
FI875411L (fi) Foerfarande och anordning foer inriktning och laengsriktad foerskjutning av avrundade burkars kanter i foerhaollande till en svetsanordning.
FI945442A0 (fi) Uudet 7beta-substituoidut 4-atsa-5alfa-kolestanonit 5alfa-reduktaasi-inhibiittoreina
FI930561L (fi) Nya svampstammar och deras anvaendning i produktion av antibioter
FI924934L (fi) Nya ftalaziner som innehaoller en eter- eller tioetergruppering i 1-staellning och foerfarande foer deras framstaellning
FI951992A0 (fi) Uusia substituoituja atsetidinoneja anti-inflammatorisina ja antidegeneratiivisina aineina
FI930716L (fi) Nya arylkarbonylaminoalkyldihydrooxopyridiner, framstaellning och anvaendning av dessa
FI932863L (fi) Foerfarande foer framstaellning av nya tienotiazinderivat och deras anvaendning
FI935117A0 (fi) Nya antiinflammatoriska isoxazoliner
FI850607L (fi) Foerfarande foer avlaegsnande av loesta och i kolloidal form varande stormolekyliga organiska aemnen ur traefoeraedlingsindustrins avfallsvatten.
FI883135A (fi) Homocyklostatin och cyklostatin innehaollande polypeptider som antihypertensiva medel.
GR880100196A (el) Υποκατεστημενα 1,3-διοξολαν-και 1,3-διοξαν-παραγωγα,μεθοδοι για την παρασκευη τους και η χρηση τους
FI923817L (fi) Nya reaktiva polyesterhartser och foerfarande foer framstaellning av dessa
KR940011228U (ko) 고속/고안정 앰프
FI915019A0 (fi) Nya 11-metylenestr-15-ener och kompositioner innehaollande desamma foer anvaendning som preventivmedel.
FI933146A (fi) Karbocykliska och heterocykliska fusionerade dihydropyridiner som kardioskyddande medel och nya heterocykliska och karbocykliska fusioneradedihydropyridiner, foerfarande foer deras framstaellning och mellanprodukter foer deras framstaellning

Legal Events

Date Code Title Description
FA Application withdrawn

Owner name: MERCK & CO., INC.